The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using FDG PET in luminal HER2-negative breast cancer.
Olivier Humbert
No relevant relationships to disclose
Alina Berriolo-Riedinger
No relevant relationships to disclose
Alexandre Cochet
No relevant relationships to disclose
Mélanie Gauthier
No relevant relationships to disclose
Celine Charon-Barra
No relevant relationships to disclose
Isabelle Desmoulins
No relevant relationships to disclose
Séverine Guiu
No relevant relationships to disclose
Michel Toubeau
No relevant relationships to disclose
Inna Dygai-Cochet
No relevant relationships to disclose
Charles Coutant
No relevant relationships to disclose
Pierre Fumoleau
Consultant or Advisory Role - Janssen (U); Roche (U); Sanofi (U)
Francois Brunotte
No relevant relationships to disclose